Search results for "Insulin"

Self-concept and adaptation to illness in pediatric diabetic patients

2014

Nuestro objetivo es estudiar el autoconcepto y la adaptación a la enfermedad en pacientes pediátricos diabéticos. Como instrumentos de evaluación se utilizaron el registro ad-hoc para las variables sociodemográficas y de enfermedad, el cuestionario de Autoconcepto Garley (CAG) y cuestionario de respuesta adaptativa a la enfermedad en pacientes diabéticos. La muestra constó de 23 sujetos evaluados en un único momento de medida, todos ellos niños y adolescentes entre 8 y 16 años de edad. Los resultados muestran cómo aproximadamente el 50% de niños y adolescentes con diabetes tipo I presentan un autoconcepto bajo en la mayoría de las dimensiones estudiadas, destacando cómo cerca del 30% de los…

Gene therapy for type 1 diabetes: is it ready for the clinic?

1999

This review, in addition to updating the growing list of type 1 diabetes- relevant gene therapies, offers an outline of short-term objectives that can readily be met to move, at least, adenoviral and adeno-associated viral-based protocols into the clinic, first as a means of facilitating islet allografts as well as platforms with which to introduce immunoregulatory transgenes. A wide array of genes have been tested to restore insulin production, to drive the differentiation of insulin-producing progenitors, and to confer immunosuppression in an antigen- and tissue-restricted manner.

Halloysite nanotubes for efficient loading, stabilization and controlled release of insulin

2018

Hypothesis: Oral insulin administration is not actually effective due to insulin rapid degradation, inactivation and digestion by proteolytic enzymes which results in low bioavailability. Moreover insulin is poorly permeable and lack of lipophilicity. These limits can be overcome by the loading of protein in some nanostructured carrier such as halloysite nanotubes (HNTs). Experiments: Herein we propose an easy strategy to obtain HNT hybrid materials for the delivery of insulin. We report a detailed description on the thermal behavior and stability of insulin loaded and released from the HNTs hybrid by the combination of several techniques. Findings: Release experiments of insulin from the H…

Nutraceuticals in Lipid-Lowering Treatment

2014

Lipid-lowering drugs may cause adverse effects and, although lipid targets may be achieved, a substantial residual cardiovascular (CV) risk remains. Treatment with agents mimicking proteins present in the body, such as incretin-based therapies, provided promising results. However, in order to improve lipids and CV risk, lifestyle measures remain important. Some researchers focused on nutraceuticals that may beneficially affect metabolic parameters and minimize CV risk. Chitosan, a dietary fiber, can regulate lipids with benefit on anthropometric parameters. The beneficial properties of dietary supplements (such as green tea extract, prebiotics, plant sterols, and stanols) on plasma lipids,…

Valor de la testosterona en saliva en el diagnóstico de la enfermedad de Alzheimer

2019

[Non-indicated insulin treatment].

1970

171 adult- and aged-onset diabetic patients treated with insulin primarily or secondarily were subjected to an attempted therapy with the additional administration of oral antidiabetic drugs. The new potent antidiabetic drug, glybenclamide (HB 419 = Daonil), was employed on a vast scale in order to carry out an oral monotherapy in the proper indications also combined with biguanides. In the 52 % of patients in study with the additional oral therapy the insulin dose could be remarkably decreased, in the 24 % of cases insulin could be at all abolished. In another 24 % of controlled cases no decrease in insulin need was found. A body weight decrease could be obtained rather in the group of pat…

Caffeine and cardiovascular diseases: critical review of current research.

2015

Caffeine is a most widely consumed physiological stimulant worldwide, which is consumed via natural sources, such as coffee and tea, and now marketed sources such as energy drinks and other dietary supplements. This wide use has led to concerns regarding the safety of caffeine and its proposed beneficial role in alertness, performance and energy expenditure and side effects in the cardiovascular system. The question remains "Which dose is safe?", as the population does not appear to adhere to the strict guidelines listed on caffeine consumption. Studies in humans and animal models yield controversial results, which can be explained by population, type and dose of caffeine and low statistica…

Aerosolized GLP-1 for Treatment of Diabetes Mellitus and Irritable Bowel Syndrome

2014

Diabetes is a global burden and the prevalence of the disease, in particular diabetes mellitus type 2 is rapidly increasing worldwide. After introduction of insulin into clinical therapy about 90 years ago a major number of pharmaceuticals has been developed for treatment of diabetes mellitus type 2. One of these, the incretin glucagon-like peptide 1 (GLP-1), like insulin, needs subcutaneous administration causing inconvenience to patients. However, administration of GLP-1 plays also a role for treatment of irritable bowel syndrome (IBS). To improve patient convenience inhaled insulin (Exubera®) was developed and approved but failed market acceptance some years ago. Recently, another inhala…

Elección del agente oral más apropiado, en monoterapia o en combinación, en el paciente anciano con diabetes

2010

The elderly patient with diabetes presents a series of features that we need to have in mind when considering drug therapy, such as quality of life, presence of chronic complications, major geriatric syndromes, and patient preferences. The limited evidence available due to the few studies performed in the elderly explains the limited existing recommendations in the most current clinical practice guidelines. Metformin is the drug of choice as monotherapy and its dosage should be adjusted to the degree of renal failure, a situation very common in the elderly. Other pharmacologic groups can also be used taking into account their limitations and contraindications. There is no consensus on what …

Menopause and diabetes: EMAS clinical guide

2018

Abstract Introduction Whether menopause increases the risk of type 2 diabetes mellitus (T2DM) independently of ageing has been a matter of debate. Controversy also exists about the benefits and risks of menopausal hormone therapy (MHT) in women with T2DM. Aims To summarise the evidence on 1) the effect of menopause on metabolic parameters and the risk of T2DM, 2) the effect of T2DM on age at menopause, 3) the effect of MHT on the risk of T2DM, and 4) the management of postmenopausal women with T2DM. Materials and methods Literature review and consensus of experts’ opinions. Results and conclusion Metabolic changes during the menopausal transition include an increase in and the central redis…